TOP2A
ENSG00000131747
Target class
Enzyme
Chromosome
17
Approved drugs
13
Clinical candidates (approved and in development)
22
- Approved drugs
- 13
- Clinical candidates (approved and in development)
- 22
- Chemical probe available
- No
- Target name
- TOP2A
- Gene name
- DNA topoisomerase II alpha
- Gene symbol
- TOP2A
- Previous gene symbols
- TOP2
- Protein name
- DNA topoisomerase 2-alpha (EC 5.6.2.2) (DNA topoisomerase II, alpha isozyme)
- TOP2alpha
- TOPIIA
- Gene biotype
- Protein coding
- Gene family
- Topoisomerases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 16
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 150.71
- Tissue specificity (Gini)
- 0.888
- Tissue specificity (tau)
- 0.971
- KEGG gene identifiers
- hsa:7153
- Protein interaction confidence
- 0.85289
- Protein interaction partners
- 136
- R-HSA-1362277
- R-HSA-4615885
- End position
- 40417896
- Start position
- 40388525
- Chromosome
- 17
- Strand
- Reverse
- Cytoplasm . Nucleus, nucleoplasm . Nucleus . Nucleus, nucleolus .
- Nucleoli
- Nucleoplasm
- PubMed 9155056
- PubMed 8299728
- PubMed 17567603
- PubMed 22013166
- Tissue specificity (tau)
- 0.971476
- Expression inequality (Gini)
- 0.887819
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 150.71
- Testis
- 78.92
- Cells - Cultured fibroblasts
- 66.69
- Esophagus - Mucosa
- 20.5
- Small Intestine - Terminal Ileum
- 8.4
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes150.71
- Testis78.92
- Cells - Cultured fibroblasts66.69
- Esophagus - Mucosa20.5
- Small Intestine - Terminal Ileum8.4
- Skin - Sun Exposed (Lower leg)7.17
- Skin - Not Sun Exposed (Suprapubic)6.79
- Vagina6.73
- Colon - Transverse5.87
- Spleen5.31
- Lung2.37
- Stomach1.68
- Minor Salivary Gland1.51
- Adrenal Gland1.19
- Whole Blood1.11
- Artery - Coronary1
- Breast - Mammary Tissue0.92
- Adipose - Subcutaneous0.86
- Thyroid0.79
- Artery - Aorta0.75
- Adipose - Visceral (Omentum)0.72
- Prostate0.69
- Cervix - Endocervix0.69
- Bladder0.67
- Nerve - Tibial0.64
And 29 more, listed on the interactive page.
- GO:0006265
- GO:0006325
- GO:0006974
- GO:0007059
- GO:0030263
- GO:0043065
- GO:0045870
- GO:0000228
- GO:0005634
- GO:0005654
- GO:0005730
- GO:0005737
- GO:0005814
- GO:0009330
- GO:0032991
- GO:1990904
- GO:0000287
- GO:0003677
- GO:0003682
- GO:0003723
- GO:0003918
- GO:0005080
- GO:0005515
- GO:0008094
- GO:0008301
- GO:0042803
- GO:0043130
- GO:0046982
Related records
Trials (3,767)
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors
- 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
- 6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
- 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- 64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets
- 8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer
- 9-ING-41 in Patients With Advanced Cancers
- A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma
- A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection
- A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia
- A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)
- A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer
Drugs (26)
- Aldoxorubicin DNA topoisomerase II alpha inhibitor
- Amrubicin DNA topoisomerase II alpha inhibitor
- Amrubicin hydrochloride DNA topoisomerase II alpha inhibitor
- Amsacrine DNA topoisomerase II inhibitor
- Becatecarin DNA topoisomerase II inhibitor
- Berubicin DNA topoisomerase II inhibitor
- Berubicin hydrochloride DNA topoisomerase II inhibitor
- C-1311 DNA topoisomerase II inhibitor
- Daunorubicin DNA topoisomerase II alpha inhibitor
- Daunorubicin citrate DNA topoisomerase II alpha inhibitor
- Daunorubicin hydrochloride DNA topoisomerase II alpha inhibitor
- Dexrazoxane DNA topoisomerase II inhibitor
- Dexrazoxane hydrochloride DNA topoisomerase II inhibitor
- Doxorubicin DNA topoisomerase II alpha inhibitor
- Doxorubicin hydrochloride DNA topoisomerase II alpha inhibitor
- Etoposide DNA topoisomerase II inhibitor
- Etoposide phosphate DNA topoisomerase II alpha inhibitor
- Gancotamab DNA topoisomerase II alpha inhibitor
- Idarubicin DNA topoisomerase II alpha inhibitor
- Idarubicin hydrochloride DNA topoisomerase II alpha inhibitor